Understanding SGLT2 Inhibitors

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are oral medications widely used in the management of type 2 diabetes. They work by selectively inhibiting the SGLT2 protein in the proximal renal tubules, which is responsible for reabsorbing approximately 90% of the filtered glucose back into the bloodstream. By blocking this protein, SGLT2 inhibitors promote glucosuria—the excretion of glucose into the urine—thereby lowering plasma glucose concentrations independently of insulin secretion or action. This unique mechanism also confers additional benefits such as modest weight loss and blood pressure reduction, making them a cornerstone of contemporary diabetes care. However, because these drugs alter renal glucose handling, they require careful monitoring to ensure both efficacy and safety.

Beyond glycemic control, SGLT2 inhibitors have shown cardiovascular and renal protective effects in large outcome trials, leading to their expanded use in patients with heart failure and chronic kidney disease, regardless of the presence of diabetes. This broadens the patient population using these agents, heightening the need for comprehensive monitoring strategies that account for both glycemic and non-glycemic effects.

Why Monitoring Blood Glucose Is Important

Regular blood glucose monitoring is critical when taking SGLT2 inhibitors, even though these medications carry a lower intrinsic risk of hypoglycemia compared to sulfonylureas or insulin. Because SGLT2 inhibitors increase urinary glucose excretion, they can lower blood glucose levels, especially when combined with other glucose-lowering therapies. The risk of hypoglycemia rises significantly if the patient is also using insulin or insulin secretagogues, requiring more frequent self-monitoring of blood glucose (SMBG).

One of the most serious concerns associated with SGLT2 inhibitors is euglycemic diabetic ketoacidosis (DKA)—a condition in which the blood glucose level may be only mildly elevated (less than 250 mg/dL) but ketones are dangerously high. Classic symptoms of DKA (polyuria, polydipsia, nausea, vomiting) may be absent or blunted because the glucose level does not reflect the metabolic crisis. This makes routine blood glucose monitoring alone insufficient; patients and clinicians must be vigilant for signs of acidosis and, in certain clinical scenarios, measure blood or urine ketone levels. The FDA has issued safety communications emphasizing the need for patient education on recognizing and managing DKA while on SGLT2 inhibitors.

Additionally, monitoring helps detect dehydration, volume depletion, and acute kidney injury—all potential adverse effects of SGLT2 inhibitors, particularly in elderly patients or those taking diuretics. By tracking blood glucose trends and correlating them with symptoms, clinicians can adjust therapy to prevent complications.

How to Monitor Blood Glucose Levels

For patients on SGLT2 inhibitors, the frequency and timing of blood glucose checks should be individualized based on the overall diabetes regimen, the presence of comorbidities, and the patient's lifestyle. The American Diabetes Association Standards of Care recommend that individuals using insulin or sulfonylureas test their blood glucose at least four times daily, while those on SGLT2 inhibitors alone or with metformin may test less frequently—often once or twice daily—to confirm glycemic control and detect trends.

Key times to measure include fasting (upon waking), pre-meals, post-meals (1–2 hours after starting a meal), and at bedtime. Fasting readings help assess basal glucose control, while postprandial checks reveal the impact of dietary choices and the medication's effect on meal-related glucose spikes. If the patient is using insulin or an insulin secretagogue, testing before each meal and at bedtime is essential to titrate doses and prevent hypoglycemia. For those who are prone to DKA (for example, during periods of illness, fasting, or surgery), more frequent monitoring—including ketone testing—is warranted.

The use of continuous glucose monitors (CGMs) has become increasingly common in type 2 diabetes management. CGMs provide real-time glucose readings and trend arrows, helping patients and clinicians detect hyperglycemia and hypoglycemia patterns that might otherwise go unnoticed. While not yet universally recommended for all patients on SGLT2 inhibitors, CGMs can be particularly valuable for those at risk of euglycemic DKA because they can alert users to rising glucose before symptoms develop. However, it is crucial to note that CGMs measure interstitial glucose, which may lag behind blood glucose during rapid changes. Therefore, a confirmatory fingerstick is advised if the CGM reading does not match symptoms or if DKA is suspected.

Using a Blood Glucose Meter Effectively

To obtain accurate results, patients should use a calibrated, quality-controlled glucose meter. Technique matters: wash hands before testing, use a fresh lancet, and ensure the test strip is not expired. Record readings in a logbook or a smartphone app (many meters sync via Bluetooth) along with notes on meals, physical activity, and any symptoms such as extreme thirst, nausea, or abdominal pain. This log becomes a critical tool during clinical visits, allowing the care team to adjust the SGLT2 inhibitor dose or add/remove other agents.

Additional Monitoring Beyond Glucose

Ketone Monitoring

Because SGLT2 inhibitors can precipitate euglycemic DKA, the FDA recommends that all patients have a means to test for ketones—either blood beta-hydroxybutyrate meters or urine ketone strips. Blood ketone testing is preferred because it provides a more accurate, real-time assessment of metabolic status. Patients should be instructed to test for ketones if they experience symptoms such as nausea, vomiting, abdominal pain, fatigue, or dyspnea, even if blood glucose is within normal range. If ketones are moderate or high (≥1.0 mmol/L in blood), immediate medical attention is required, and the SGLT2 inhibitor should be temporarily discontinued.

Special situations that increase DKA risk include prolonged fasting (for procedures, illness, or personal reasons), acute infections, excessive alcohol intake, and very low-carbohydrate diets. In these contexts, patients may need to suspend SGLT2 inhibitor therapy for 24–48 hours and monitor blood glucose and ketones more frequently. The literature emphasizes that patient education on the signs of DKA is as important as glucose monitoring itself.

Renal Function and Hydration Status

SGLT2 inhibitors reduce intravascular volume and can cause acute declines in estimated glomerular filtration rate (eGFR), especially in the first weeks of therapy. Monitoring serum creatinine and eGFR before starting therapy and periodically thereafter is standard of care. The FDA recommends assessing renal function before initiation and at least annually, with more frequent checks in patients with eGFR <60 mL/min/1.73 m² or in those taking concomitant diuretics, ACE inhibitors, or ARBs. Blood pressure and weight should also be tracked to identify volume depletion early.

Patients should be counseled to maintain adequate hydration—aiming for 6–8 glasses of fluid daily unless contraindicated—and to recognize signs of dehydration such as dizziness, dry mouth, and decreased urine output. In hot weather or during increased physical activity, fluid intake may need to be increased further.

Special Considerations for Different Populations

Elderly Patients

Older adults are more susceptible to the volume-depleting effects of SGLT2 inhibitors, including orthostatic hypotension and falls. Baseline and ongoing monitoring of blood glucose, renal function, and electrolytes is essential. In this population, glycemic targets may be less stringent, and the risks of hypoglycemia and DKA may outweigh cardiovascular benefits if monitoring is not rigorous. A careful review of all medications (especially diuretics and NSAIDs) is necessary before initiating therapy.

Patients with Chronic Kidney Disease

While SGLT2 inhibitors are now approved for use in patients with chronic kidney disease (CKD) with eGFR as low as 20 mL/min/1.73 m², glycemic efficacy decreases as renal function declines because fewer nephrons are available to excrete glucose. Nevertheless, the cardiorenal benefits persist. For these patients, monitoring focuses more on renal safety (creatinine, potassium, bicarbonate) and DKA prevention than on glucose lowering. The dose of the SGLT2 inhibitor may need adjustment based on the specific drug's label.

During Illness, Surgery, or Periods of Fasting

The American Diabetes Association and the Society for Ambulatory Anesthesia recommend temporarily stopping SGLT2 inhibitors 3–4 days before elective surgery and during acute medical illnesses. During these times, patients should be instructed to test blood glucose and ketones more frequently. If ketones become elevated, medical evaluation is needed, and the medication should be withheld until the patient is stable and consuming adequate carbohydrates.

Pregnancy and Lactation

SGLT2 inhibitors are not recommended during pregnancy or breastfeeding due to lack of safety data and potential risks to the fetus (including possible kidney toxicity). Women of childbearing age should be advised on effective contraception. If pregnancy is planned, these medications should be discontinued and replaced with insulin.

Consult Your Healthcare Provider

Blood glucose monitoring data should be reviewed with the healthcare team at every visit. Trends over time—not just individual readings—guide therapeutic decisions. For patients on SGLT2 inhibitors, a downward trend in fasting glucose may allow dose reduction of concomitant insulin or sulfonylureas, while persistent hyperglycemia may indicate the need for a different agent or combination therapy. Any episode of documented hypoglycemia, especially severe (<54 mg/dL), warrants immediate medication adjustment. Similarly, episodes of nausea, fatigue, or breathlessness should prompt an investigation for DKA, even if blood glucose is normal.

It is also important to ensure that patients understand their medication regimen—what to do if a dose is missed, when to take it (before the first meal of the day for most agents to reduce postprandial exposure), and how to store test strips and meters. The pharmacist and diabetes educator play key roles in reinforcing these messages. For the most current guidance, the ADA's cardiovascular and kidney protection recommendations provide an evidence-based framework for monitoring while on SGLT2 inhibitors.

Ultimately, the success of SGLT2 inhibitor therapy depends on a partnership between the patient and the care team, anchored by meticulous monitoring. Blood glucose checks are the heartbeat of that partnership, but they must be combined with vigilance for ketones, renal function, hydration, and subtle clinical changes. With proper monitoring, these powerful medications can be used safely to achieve glycemic targets and reduce long-term cardiovascular and renal risk.